{"entity":{"id":"nct03417882","kind":"trial","name":"GRN-1201 With Pembrolizumab in Subjects With Metastatic PD-L1+ NSCLC","aka":[],"tldr":"A phase 2 trial of GRN-1201 run by BrightPath Biotherapeutics, terminated.","summary":"GRN-1201 With Pembrolizumab in Subjects With Metastatic PD-L1+ NSCLC is a phase 2 interventional study registered as NCT03417882 by BrightPath Biotherapeutics, with 20 participants enrolled, started 2019-01-03. Conditions recorded: Metastatic NSCLC. Interventions recorded: GRN-1201 + Pembrolizumab.","status":"historic","asOf":"2026-11-03","links":[{"label":"ClinicalTrials.gov NCT03417882","url":"https://clinicaltrials.gov/study/NCT03417882"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":["grn-1201"],"companies":["brightpath-biotherapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT03417882","phase":"2","setting":"A Pilot, Open-Label, Multi-Center, Multi-Dose Study of GRN-1201 Added to Pembrolizumab in Subjects With Non-Small Cell Lung Cancer With High PD-L1 Expression","sponsor":"BrightPath Biotherapeutics","enrolled":20,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct03417882/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"drug":[{"id":"grn-1201","kind":"drug","name":"GRN-1201","route":"/drugs/grn-1201/"}],"company":[{"id":"brightpath-biotherapeutics","kind":"company","name":"BrightPath Biotherapeutics","route":"/companies/brightpath-biotherapeutics/"}]}}